Baird Maintains Bullish View on Sarepta Therapeutic (SRPT) Following WMS Update
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $47 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they remain ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
